Loading...
•
Dec 31, 2021
Edwards Lifesciences Q4 2021 Earnings Report
Reported fourth quarter results with sales growth despite Omicron impact.
Key Takeaways
Edwards Lifesciences reported a 12% increase in Q4 sales to $1.33 billion, with underlying growth of 13%. Adjusted EPS was $0.51. The company reaffirmed its full-year 2022 sales guidance and adjusted EPS expectations.
2021 sales grew 19 percent, or 18 percent on an underlying basis
Q4 sales grew 12 percent to $1.33 billion; underlying 13 percent
Q4 TAVR sales grew 12 percent; underlying 13 percent
Q4 EPS was $0.53; adjusted EPS was $0.51
Edwards Lifesciences
Edwards Lifesciences
Edwards Lifesciences Revenue by Segment
Edwards Lifesciences Revenue by Geographic Location
Revenue by Segment
TAVR Revenue
CapyFin.comTMTT Revenue
CapyFin.comSurgical Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.comJapan Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
The company is reaffirming the sales guidance it provided at the December investor conference for all product groups. Full year 2022 sales are expected to grow at a low double-digit rate to $5.5 to $6.0 billion. Additionally, the company continues to expect full year 2022 adjusted earnings per share of $2.50 to $2.65.
Positive Outlook
- Full year 2022 sales are expected to grow at a low double-digit rate to $5.5 to $6.0 billion.
- The company continues to expect full year 2022 adjusted earnings per share of $2.50 to $2.65.
- For the first quarter of 2022, the company projects total sales to be between $1.27 and $1.35 billion.
- For the first quarter of 2022, the company projects adjusted EPS of $0.54 to $0.62.
- We are enthusiastic about the continued expansion of transcatheter-based therapies for the many structural heart patients still in need, which positions us well for long-term success
Revenue & Expenses
Visualization of income flow from segment revenue to net income